Literature DB >> 21300978

The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.

Junmei Chen1, William E Hobbs, Jennie Le, Peter J Lenting, Philip G de Groot, José A López.   

Abstract

Vaso-occlusion, hemolysis, and oxidative stress are hallmarks of sickle cell disease (SCD). This pathology is accompanied by systemic endothelial activation, rendering the endothelium more adhesive for blood cells, including sickle erythrocytes. Activated endothelial cells display or secrete several adhesive molecules, including von Willebrand factor (VWF). We assessed several VWF parameters in SCD patients at baseline: multimer pattern, antigen concentration (VWF:Ag), activation factor (VWF:AF), and total active VWF (VWF:TA). VWF:AF was determined using a llama nanobody (AU/VWFa-11) that detects a platelet-binding conformation of the A1 domain; VWF:TA was calculated by multiplying VWF:Ag by VWF:AF. SCD plasma contained elevated VWF:Ag and ultralarge VWF multimers. VWF:TA, a measure of total VWF reactivity, correlated closely with hemolysis, as determined by serum lactate dehydrogenase. ADAMTS13 activity and antigen were normal in all patients. These findings suggest an important role for hyperreactive VWF in SCD pathology and connect SCD to other microangiopathies, particularly thrombotic thrombocytopenic purpura.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21300978      PMCID: PMC3072883          DOI: 10.1182/blood-2010-08-302539

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Inflammatory mediators promote strong sickle cell adherence to endothelium under venular flow conditions.

Authors:  Paula S Walmet; James R Eckman; Timothy M Wick
Journal:  Am J Hematol       Date:  2003-08       Impact factor: 10.047

2.  Thrombotic thrombocytopenic purpura in a patient with sickle cell crisis.

Authors:  J Bolaños-Meade; Y K Keung; C López-Arvizu; R Florendo; E Cobos
Journal:  Ann Hematol       Date:  1999-12       Impact factor: 3.673

3.  Sickle erythrocyte adherence to vascular endothelium. Morphologic correlates and the requirement for divalent cations and collagen-binding plasma proteins.

Authors:  N Mohandas; E Evans
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

4.  Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.

Authors:  J L Moake; C K Rudy; J H Troll; M J Weinstein; N M Colannino; J Azocar; R H Seder; S L Hong; D Deykin
Journal:  N Engl J Med       Date:  1982-12-02       Impact factor: 91.245

5.  Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease.

Authors:  R P Hebbel; O Yamada; C F Moldow; H S Jacob; J G White; J W Eaton
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

6.  N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice.

Authors:  Junmei Chen; Adili Reheman; Francisca C Gushiken; Leticia Nolasco; Xiaoyun Fu; Joel L Moake; Heyu Ni; José A López
Journal:  J Clin Invest       Date:  2011-01-25       Impact factor: 14.808

7.  Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers.

Authors:  Maneesh Arya; Bahman Anvari; Gabriel M Romo; Miguel A Cruz; Jing-Fei Dong; Larry V McIntire; Joel L Moake; José A López
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

8.  Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes.

Authors:  R S Schwartz; Y Tanaka; I J Fidler; D T Chiu; B Lubin; A J Schroit
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

9.  Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow.

Authors:  T M Wick; J L Moake; M M Udden; S G Eskin; D A Sears; L V McIntire
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

10.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.

Authors:  Jing-fei Dong; Joel L Moake; Leticia Nolasco; Aubrey Bernardo; Wendy Arceneaux; Corie N Shrimpton; Alicia J Schade; Larry V McIntire; Kazuo Fujikawa; José A López
Journal:  Blood       Date:  2002-07-25       Impact factor: 22.113

View more
  37 in total

1.  Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease.

Authors:  Enrico M Novelli; Gregory J Kato; Mariana E Hildesheim; Suchitra Barge; Michael P Meyer; Jay Lozier; Andrea Cortese Hassett; Margaret V Ragni; Jeffrey S Isenberg; Mark T Gladwin
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

Review 2.  Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Authors:  Ram Kalpatthi; Enrico M Novelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Pulmonary complications of sickle cell disease.

Authors:  Andrew C Miller; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

4.  A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria.

Authors:  Niamh O'Regan; Kristina Gegenbauer; Jamie M O'Sullivan; Sanaz Maleki; Teresa M Brophy; Niall Dalton; Alain Chion; Padraic G Fallon; Georges E Grau; Ulrich Budde; Owen P Smith; Alister G Craig; Roger J S Preston; James S O'Donnell
Journal:  Blood       Date:  2015-10-28       Impact factor: 22.113

5.  Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab.

Authors:  Satheesh Chonat; Shanmuganathan Chandrakasan; Karen Ann Kalinyak; David Ingala; Ralph Gruppo; Theodosia A Kalfa
Journal:  Br J Haematol       Date:  2015-12-21       Impact factor: 6.998

6.  What is behind a relapse of thrombotic thrombocytopenic purpura?

Authors:  Marco Capecchi; Andrea Artoni; Maria Domenica Cappellini; Giovanna Graziadei
Journal:  Intern Emerg Med       Date:  2017-11-02       Impact factor: 3.397

Review 7.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

8.  Normal cleavage of von Willebrand factor by ADAMTS-13 in the absence of factor VIII in patients with severe hemophilia A.

Authors:  J Chen; D W Chung; J Le; M Ling; B A Konkle; J A López
Journal:  J Thromb Haemost       Date:  2013-09       Impact factor: 5.824

Review 9.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

10.  Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.

Authors:  Anwar Al-Awadhi; Adekunle Adekile; Rajaa Marouf
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.